Eli Lilly Soars on Blockbuster Weight-Loss Drug Sales, Raises 2025 Outlook

Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.